CD4 and neoplasm: As expected from the relatively low response rates in patients with NSCLC, CD4+ T cells were significantly enriched in the tumor margin, whereas only a few patients presented increased CD4+ T cell accumulation within the tumor core between baseline and after αPD-L1 treatment (Fig. 6B).